Editorial · 31 Jan 2025
Review articlePublished 16 Jun 2017
Harnessing the Immune Regulatory Balance of Toll-like Receptor 9 Agonists in Cancer Immunotherapy.
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Toll-like receptor 9 (TLR9), a naturally existing immune regulatory site, not only takes part in enhancing anti-tumor immunity but also promoting the immunosuppressive environment of the growing tumor. TLR9 has shown its potential activity as a therapeutic target in cancer immunotherapy. However, the increased pro-tumor inflammation mediated by TLR9 should also be considered. Therefore, it is important to develop a better understanding of its regulatory mechanisms to improve the therapeutic efficacy. This review will discuss the mechanisms of immune homeostasis regulated by TLR9 signaling pathways, and also introduce the strategies of how to harness the immune regulatory balance by TLR9 agonists, CpG oligodeoxynucleotides, in cancer immunotherapies.
Keywords
Subjects
Immunology & MicrobiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Immunology Case Reports.
Editorial · 31 Jan 2025
Vaccination Strategies: Lessons from Parasitic Antigenicity
Editorial · 31 Jan 2025
Trained Immunity and Parasitic Infections: Rethinking Adaptive Boundaries
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalImmunology Case Reports
- SubjectImmunology & Microbiology
- BylineArticles whose byline prints “Cui J”
- BylineArticles whose byline prints “Bai L”
- BylineArticles whose byline prints “Zhou L”
- BylineArticles whose byline prints “Chen W”
- BylineArticles whose byline prints “Chen J”
